tiprankstipranks
Trending News
More News >
Micro-X Ltd. (AU:MX1)
ASX:MX1
Australian Market

Micro-X Ltd. (MX1) AI Stock Analysis

Compare
9 Followers

Top Page

AU:MX1

Micro-X Ltd.

(Sydney:MX1)

Select Model
Select Model
Select Model
Neutral 41 (OpenAI - 5.2)
Rating:41Neutral
Price Target:
AU$0.09
▼(-12.00% Downside)
Micro-X Ltd. is facing substantial financial difficulties, with declining revenues and persistent losses being the most significant factors impacting the score. The technical analysis indicates a bearish trend, and the valuation metrics highlight ongoing profitability issues. These factors collectively result in a low overall stock score.
Positive Factors
High gross margin
A 79% gross margin signals strong unit economics and pricing power in Micro-X’s core imaging hardware. Persistently high gross margin provides a structural buffer to fund R&D and scale service operations, improving long-term profitability prospects if operating costs are controlled.
Proprietary CNT X‑ray technology
Carbon nanotube-enabled portable X-ray systems represent a durable competitive advantage: differentiated technology, product portability, and applicability across medical and security markets. Such IP and product differentiation raise entry barriers and support sustainable market positioning over time.
Recurring service & partnership revenue
Long-term service agreements and partnerships create recurring revenue potential and higher customer lifetime value. This business model element improves revenue visibility and resilience, enabling stable aftermarket income that can cushion product sales cyclicality and support long-term cash generation.
Negative Factors
Declining revenue trend
Sustained revenue decline reduces scale benefits and undermines the firm’s ability to convert strong gross margins into operating leverage. A shrinking top line pressures investment in R&D, commercialization and service expansion, weakening long-term competitive positioning if growth is not restored.
Negative operating and free cash flow
Persistent negative operating and free cash flows impair the company’s capacity to self-fund operations and growth. Over months to years this increases reliance on external financing, raises dilution or refinancing risk, and constrains strategic investments in product development and market expansion.
Rising leverage and negative ROE
An increased debt-to-equity ratio combined with negative ROE signals deteriorating balance sheet resilience. Higher leverage raises fixed costs and reduces financial flexibility, making the company more vulnerable to demand shocks and limiting its ability to invest in commercialization or absorb prolonged losses.

Micro-X Ltd. (MX1) vs. iShares MSCI Australia ETF (EWA)

Micro-X Ltd. Business Overview & Revenue Model

Company DescriptionMicro-X Ltd. (MX1) is an innovative technology company focused on developing advanced imaging solutions primarily for the medical and security sectors. The company specializes in producing lightweight, portable X-ray systems that utilize cutting-edge carbon nanotube technology, enabling faster and more efficient imaging capabilities. Micro-X's core products include its mobile X-ray units, which are designed for both hospital use and emergency situations, as well as security screening solutions for airports and public venues.
How the Company Makes MoneyMicro-X generates revenue through the sale of its medical and security imaging systems, which include both hardware and software components. The company earns money from direct sales to hospitals, clinics, and security organizations, as well as through long-term service agreements that provide ongoing maintenance and support for its products. Additionally, Micro-X may engage in partnerships with healthcare providers and security agencies to offer tailored solutions, further enhancing their revenue potential. The company also explores opportunities in research and development contracts, which can contribute to its earnings by leveraging its technology for specialized applications.

Micro-X Ltd. Financial Statement Overview

Summary
Micro-X Ltd. faces significant financial challenges, with declining revenues, persistent losses, and negative cash flows. The company has a high gross profit margin but struggles to achieve net profitability due to high operating expenses. Increasing leverage and negative return on equity further highlight financial instability.
Income Statement
35
Negative
Micro-X Ltd. has experienced declining revenue growth, with a negative growth rate of -9.52% in the latest year. The company is struggling with profitability, as indicated by negative net profit margins and EBIT margins. Despite a high gross profit margin of 79.05%, the company is unable to translate this into net profitability due to high operating expenses and negative EBIT and EBITDA margins.
Balance Sheet
40
Negative
The company's debt-to-equity ratio has increased to 0.87, indicating a higher reliance on debt financing. Return on equity is negative, reflecting ongoing losses. The equity ratio is relatively stable, but the overall financial health is weakened by persistent losses and increasing leverage.
Cash Flow
30
Negative
Micro-X Ltd. shows negative operating and free cash flows, with a slight decline in free cash flow growth. The operating cash flow to net income ratio is negative, indicating cash flow challenges. The free cash flow to net income ratio is slightly above 1, suggesting that free cash flow is marginally better than net income, but overall cash flow performance remains weak.
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue13.05M13.05M15.22M15.01M8.97M3.77M
Gross Profit5.98M10.32M5.74M-7.11M-12.33M-12.96M
EBITDA-15.70M-11.76M-14.35M-15.54M-19.02M-13.61M
Net Income-13.89M-13.89M-9.77M-10.75M-17.09M-14.73M
Balance Sheet
Total Assets22.11M22.11M26.89M30.30M31.28M44.68M
Cash, Cash Equivalents and Short-Term Investments3.24M3.24M3.23M5.22M10.30M30.14M
Total Debt6.53M6.53M3.99M4.70M5.31M5.84M
Total Liabilities14.56M14.56M12.63M13.17M12.05M10.53M
Stockholders Equity7.55M7.55M14.26M17.13M19.22M34.15M
Cash Flow
Free Cash Flow-8.69M-8.69M-6.80M-11.77M-19.22M-10.76M
Operating Cash Flow-8.59M-8.59M-6.43M-10.99M-18.11M-9.86M
Investing Cash Flow-100.00K-100.00K-369.00K-779.00K-1.11M-901.00K
Financing Cash Flow8.71M8.71M4.81M6.69M-612.00K22.57M

Micro-X Ltd. Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.10
Price Trends
50DMA
0.09
Negative
100DMA
0.09
Negative
200DMA
0.08
Positive
Market Momentum
MACD
>-0.01
Positive
RSI
37.24
Neutral
STOCH
18.52
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:MX1, the sentiment is Negative. The current price of 0.1 is above the 20-day moving average (MA) of 0.09, above the 50-day MA of 0.09, and above the 200-day MA of 0.08, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 37.24 is Neutral, neither overbought nor oversold. The STOCH value of 18.52 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:MX1.

Micro-X Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
51
Neutral
AU$23.48M-2.53-103.74%14.84%39.64%
50
Neutral
AU$2.02B-48.38-44.49%55.91%22.60%
46
Neutral
AU$125.58M-10.18-31.98%34.20%-23.90%
44
Neutral
AU$164.50M-15.34-70.55%-257.32%
43
Neutral
AU$54.08M-106.45-2.50%25.72%84.69%
41
Neutral
AU$65.35M-3.76-128.19%-14.25%-22.83%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:MX1
Micro-X Ltd.
0.09
<0.01
6.25%
AU:CYC
Cyclopharm Limited
1.23
-0.99
-44.59%
AU:CSX
CleanSpace Holdings Ltd.
0.66
0.22
50.00%
AU:EMV
EMvision Medical Devices Ltd.
1.76
-0.05
-2.76%
AU:CBL
Control Bionics Ltd.
0.06
0.00
0.00%
AU:4DX
4DMedical Ltd
3.43
2.89
535.19%

Micro-X Ltd. Corporate Events

Micro-X Issues New Shares Under Incentive Plan, Confirms Ongoing Compliance
Jan 13, 2026

Micro-X Ltd has issued 2,255,927 fully paid ordinary shares under its incentive plan, expanding its share capital as part of its employee and executive remuneration structure. The company has confirmed that the shares were issued without a prospectus in reliance on existing disclosure provisions, and that it remains compliant with financial reporting and continuous disclosure obligations, with no additional material information required by investors to assess the company or the rights attached to the new shares, supporting transparency for existing and prospective shareholders.

The most recent analyst rating on (AU:MX1) stock is a Buy with a A$0.16 price target. To see the full list of analyst forecasts on Micro-X Ltd. stock, see the AU:MX1 Stock Forecast page.

Micro-X Seeks ASX Quotation for 1.45 Million New Shares
Jan 13, 2026

Micro-X Ltd has applied to the ASX for quotation of 1,453,664 new fully paid ordinary shares under its existing issuer code MX1. The additional shares, issued on 14 January 2026 following the exercise or conversion of existing securities, will modestly increase the company’s free float and tradable capital base, providing incremental liquidity for investors without materially altering its capital structure.

The most recent analyst rating on (AU:MX1) stock is a Buy with a A$0.16 price target. To see the full list of analyst forecasts on Micro-X Ltd. stock, see the AU:MX1 Stock Forecast page.

Micro-X Seeks ASX Quotation for New Shares Issued Under Employee Scheme
Jan 13, 2026

Micro-X Limited has applied to the ASX for quotation of 802,263 new fully paid ordinary shares issued under its employee incentive scheme. The move modestly increases the company’s quoted capital base and reflects ongoing use of equity-based compensation to attract and retain staff, aligning employee interests with shareholders without signalling a major capital raising or change in strategic direction.

The most recent analyst rating on (AU:MX1) stock is a Buy with a A$0.16 price target. To see the full list of analyst forecasts on Micro-X Ltd. stock, see the AU:MX1 Stock Forecast page.

Micro-X Issues 26.9 Million Performance Rights Under Employee Incentive Scheme
Jan 13, 2026

Micro-X Limited has issued 26,874,854 unquoted performance rights under its employee incentive scheme, as disclosed in an Appendix 3G filing dated 13 January 2026. The grant of a substantial volume of performance rights indicates an ongoing use of equity-based compensation to incentivise and retain staff, which may support talent attraction and alignment of management interests with shareholders while modestly increasing potential future dilution for existing investors.

The most recent analyst rating on (AU:MX1) stock is a Buy with a A$0.16 price target. To see the full list of analyst forecasts on Micro-X Ltd. stock, see the AU:MX1 Stock Forecast page.

Micro-X Cancels 580,293 Performance Rights in Capital Structure Adjustment
Jan 13, 2026

Micro-X Ltd., listed on the ASX under code MX1, has notified the market of changes to its issued capital structure. The announcement does not provide additional information on the company’s industry, products, or market focus.

The company has cancelled 580,293 performance rights (security code MX1AG) effective 13 January 2026, following an agreement between Micro-X and the holder. The cessation of these securities represents a minor capital structure adjustment and may marginally reduce future equity dilution for existing shareholders, but no broader operational or strategic implications were disclosed in the notice.

The most recent analyst rating on (AU:MX1) stock is a Buy with a A$0.16 price target. To see the full list of analyst forecasts on Micro-X Ltd. stock, see the AU:MX1 Stock Forecast page.

Micro-X Director Ilona Meyer’s Performance Rights Expire, Updating Equity Position
Jan 13, 2026

Micro-X Limited has reported a change in the interests of director Ilona Meyer, as required under ASX listing rules. The company disclosed that Meyer’s holding of 127,877 unlisted performance rights has lapsed due to expiry, leaving her with 589,043 fully paid ordinary shares and 52,631 unlisted options, and confirmed that no trades occurred during a closed period and no consideration was involved in the change. The update clarifies the director’s current equity exposure and removes the previously held performance rights from the company’s overhang of potential equity, offering shareholders greater transparency over board-level incentives and potential future dilution.

The most recent analyst rating on (AU:MX1) stock is a Buy with a A$0.16 price target. To see the full list of analyst forecasts on Micro-X Ltd. stock, see the AU:MX1 Stock Forecast page.

Micro-X Performance Rights Lapse, Trimming Potential Future Dilution
Jan 13, 2026

Micro-X Limited has announced the cessation of 4,103,330 performance rights (ASX code MX1AG) following their expiry without exercise or conversion on 13 January 2026. The lapse of these unexercised performance rights slightly simplifies the company’s capital structure and may modestly reduce potential future dilution for existing shareholders, but does not involve any cash movement or indicate an immediate change to operational activities.

The most recent analyst rating on (AU:MX1) stock is a Buy with a A$0.16 price target. To see the full list of analyst forecasts on Micro-X Ltd. stock, see the AU:MX1 Stock Forecast page.

Micro-X Issues 18.75 Million New Shares at $0.08 Under Placement
Dec 30, 2025

Micro-X Ltd has issued 18.75 million fully paid ordinary shares at $0.08 per share, expanding its share capital without providing a disclosure document under the fundraising provisions of the Corporations Act. The company has advised that it remains compliant with its financial reporting and continuous disclosure requirements and that there is no excluded or undisclosed information considered material for investors in assessing the company’s financial position, prospects, or the rights attached to the new shares, signalling that the capital raising is being conducted within standard regulatory settings and without additional risk disclosures for stakeholders.

The most recent analyst rating on (AU:MX1) stock is a Hold with a A$0.08 price target. To see the full list of analyst forecasts on Micro-X Ltd. stock, see the AU:MX1 Stock Forecast page.

Micro-X Seeks ASX Quotation for 18.75 Million New Shares
Dec 30, 2025

Micro-X Ltd has applied for quotation on the ASX of 18.75 million new fully paid ordinary shares, expanding the number of its listed securities. The new shares, issued on 30 December 2025 under a previously announced transaction, represent a capital raising or structural adjustment that will increase the company’s free float and potentially enhance liquidity for existing and new shareholders.

The most recent analyst rating on (AU:MX1) stock is a Hold with a A$0.08 price target. To see the full list of analyst forecasts on Micro-X Ltd. stock, see the AU:MX1 Stock Forecast page.

Micro-X Seeks ASX Quotation for 37.25 Million New Shares
Dec 24, 2025

Micro-X Ltd has applied to the ASX for quotation of 37.25 million new fully paid ordinary shares under its existing issuer code MX1. The securities, issued on 24 December 2025 as part of a previously announced transaction, will expand the company’s quoted share base, signalling a capital-raising or structural move that may affect ownership dispersion and liquidity for existing and new shareholders.

The most recent analyst rating on (AU:MX1) stock is a Hold with a A$0.08 price target. To see the full list of analyst forecasts on Micro-X Ltd. stock, see the AU:MX1 Stock Forecast page.

Micro-X Issues 37.25 Million New Shares at $0.08 Under Corporations Act Exemption
Dec 24, 2025

Micro-X Ltd has issued 37,250,000 fully paid ordinary shares at $0.08 per share, increasing its capital base through a placement conducted without a prospectus under the exemption provisions of the Corporations Act. The company confirmed it remains compliant with its financial reporting and continuous disclosure obligations and stated there is no undisclosed market-sensitive information that investors would reasonably require, signalling that the capital raising is being carried out within the standard regulatory framework and without hidden risks for existing or new shareholders.

The most recent analyst rating on (AU:MX1) stock is a Hold with a A$0.08 price target. To see the full list of analyst forecasts on Micro-X Ltd. stock, see the AU:MX1 Stock Forecast page.

Micro-X Limited Announces New Securities Issue to Boost Capital
Dec 18, 2025

Micro-X Limited announced its plan to issue up to 77,250,000 new ordinary fully paid shares, with the proposed issuance date set for December 24, 2025. This move is expected to provide additional capital, likely supporting the company’s growth initiatives and strengthening its position in the competitive medical imaging technology sector, enhancing its appeal to stakeholders and investors.

The most recent analyst rating on (AU:MX1) stock is a Hold with a A$0.08 price target. To see the full list of analyst forecasts on Micro-X Ltd. stock, see the AU:MX1 Stock Forecast page.

Micro-X Ltd. Launches $6M Capital Raising for Commercial Expansion
Dec 18, 2025

Micro-X Ltd. has announced a $6 million capital raising initiative aimed at advancing the commercialization of its technologies and achieving various near-term strategic goals. As part of the development, the company’s strategic partner will increase their stake to 8.5%, signaling strengthened collaborative engagement and potential benefits for stakeholders through enhanced industry positioning.

The most recent analyst rating on (AU:MX1) stock is a Hold with a A$0.08 price target. To see the full list of analyst forecasts on Micro-X Ltd. stock, see the AU:MX1 Stock Forecast page.

Micro-X Secures $6.18M Placement to Accelerate Imaging and Security Innovations
Dec 18, 2025

Micro-X has raised $6.18M in its latest placement to fund critical commercial and manufacturing activities. With participation from key strategic investor Billion Prima, which increased its shareholding to 8.6%, and commitments from its chairman, this funding targets scaling up production of X-ray tubes and generators, advancing medical imaging initiatives like the Head CT product, and supporting partnerships in the security asset sector.

The most recent analyst rating on (AU:MX1) stock is a Hold with a A$0.08 price target. To see the full list of analyst forecasts on Micro-X Ltd. stock, see the AU:MX1 Stock Forecast page.

Micro-X Ltd. Announces Successful 2025 AGM Results
Nov 11, 2025

Micro-X Ltd. announced the results of its 2025 Annual General Meeting, where all resolutions were carried with significant majorities. The re-election of directors and the adoption of the remuneration report were among the key resolutions passed, reflecting strong shareholder support and confidence in the company’s strategic direction.

The most recent analyst rating on (AU:MX1) stock is a Buy with a A$0.17 price target. To see the full list of analyst forecasts on Micro-X Ltd. stock, see the AU:MX1 Stock Forecast page.

Micro-X Ltd. Advances in Medical Imaging and Security Technology
Nov 11, 2025

Micro-X Ltd. has achieved significant commercial and technical milestones over the past year, including the development of a portable Head CT scanner and advancements in airport security technology. The company secured over $36 million in external funding, including a substantial contract from the US Government, and formed a co-development partnership in Asia. These achievements underscore Micro-X’s commitment to innovation and strategic growth, with a focus on expanding its product roadmap and enhancing its market presence in medical imaging and security technology.

The most recent analyst rating on (AU:MX1) stock is a Buy with a A$0.17 price target. To see the full list of analyst forecasts on Micro-X Ltd. stock, see the AU:MX1 Stock Forecast page.

Micro-X Ltd. Outlines Strategic Direction at 2025 AGM
Nov 11, 2025

Micro-X Ltd. held its 2025 Annual General Meeting, where the CEO presented a summary of the company’s current position and future prospects. The presentation emphasized that while the information provided is based on reliable sources, it may not be exhaustive, and stakeholders should conduct their own assessments. The company clarified that the presentation does not constitute an offer for securities or investment advice, and highlighted the legal limitations regarding the distribution of its securities in the United States and other jurisdictions.

The most recent analyst rating on (AU:MX1) stock is a Buy with a A$0.17 price target. To see the full list of analyst forecasts on Micro-X Ltd. stock, see the AU:MX1 Stock Forecast page.

Micro-X Ltd Expands Market Reach with Major Orders and Innovations
Oct 31, 2025

Micro-X Ltd has reported significant achievements for the quarter ending September 2025, including securing its largest order to date with a $3.3 million purchase from the Malaysian Ministry of Health for Rover Plus units. This order marks a strategic expansion into Southeast Asia and highlights the company’s growing momentum in the healthcare market. Additionally, Micro-X is advancing its Head CT technology for stroke diagnosis, with upcoming trials in Australian hospitals and a world-first deployment in ambulances, supported by a $4.4 million government grant. These developments underscore Micro-X’s commitment to expanding its market presence and enhancing its product offerings.

The most recent analyst rating on (AU:MX1) stock is a Buy with a A$0.17 price target. To see the full list of analyst forecasts on Micro-X Ltd. stock, see the AU:MX1 Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Nov 22, 2025